What will be the role of molnupiravir in the treatment of COVID-19 infection?
作者信息
Vitiello Antonio, Troiano Valentina, La Porta Raffaele
机构信息
Pharmaceutical Department Usl Umbria 1, Via XIV Settembre-75, Perugia, Italy.
出版信息
Drugs Ther Perspect. 2021;37(12):579-580. doi: 10.1007/s40267-021-00879-2. Epub 2021 Nov 5.
Abstract
摘要
相似文献
1
What will be the role of molnupiravir in the treatment of COVID-19 infection?
Drugs Ther Perspect. 2021;37(12):579-580. doi: 10.1007/s40267-021-00879-2. Epub 2021 Nov 5.
2
Molnupiravir, an Oral Antiviral Treatment for COVID-19.
medRxiv. 2021 Jun 17:2021.06.17.21258639. doi: 10.1101/2021.06.17.21258639.
3
Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent.
Antibiotics (Basel). 2021 Oct 23;10(11):1294. doi: 10.3390/antibiotics10111294.
4
Molnupiravir, favipiravir and other antiviral drugs with proposed potentials for management of COVID-19: a concern on antioxidant aspect.
Int J Biochem Mol Biol. 2022 Feb 15;13(1):1-4. eCollection 2022.
5
Engineered Ribosyl-1-Kinase Enables Concise Synthesis of Molnupiravir, an Antiviral for COVID-19.
ACS Cent Sci. 2021 Dec 22;7(12):1980-1985. doi: 10.1021/acscentsci.1c00608. Epub 2021 Oct 29.
6
Decoding molnupiravir-induced mutagenesis in SARS-CoV-2.
J Biol Chem. 2021 Jul;297(1):100867. doi: 10.1016/j.jbc.2021.100867. Epub 2021 Jun 9.
7
Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication.
iScience. 2022 May 20;25(5):104293. doi: 10.1016/j.isci.2022.104293. Epub 2022 Apr 25.
8
Cost of Goods Analysis Facilitates an Integrated Approach to Identifying Alternative Synthesis Methodologies for Lower Cost Manufacturing of the COVID-19 Antiviral Molnupiravir.
Gates Open Res. 2022 Feb 16;6:8. doi: 10.12688/gatesopenres.13509.1. eCollection 2022.
9
Progress Toward a Large-Scale Synthesis of Molnupiravir (MK-4482, EIDD-2801) from Cytidine.
ACS Omega. 2021 Apr 8;6(15):10396-10402. doi: 10.1021/acsomega.1c00772. eCollection 2021 Apr 20.
10
In nonhospitalized, unvaccinated adults with COVID-19, molnupiravir reduced hospitalization or death at 29 d.
Ann Intern Med. 2022 Apr;175(4):JC40. doi: 10.7326/J22-0017. Epub 2022 Apr 5.
引用本文的文献
1
The Value of Ursodeoxycholic Acid and Mesenchymal Stem Cells in the Treatment of Severe COVID-19.
Microorganisms. 2024 Jun 22;12(7):1269. doi: 10.3390/microorganisms12071269.
2
In-silico evaluation of natural alkaloids against the main protease and spike glycoprotein as potential therapeutic agents for SARS-CoV-2.
PLoS One. 2024 Jan 4;19(1):e0294769. doi: 10.1371/journal.pone.0294769. eCollection 2024.
3
Phenothiazines Inhibit SARS-CoV-2 Entry through Targeting Spike Protein.
Viruses. 2023 Jul 31;15(8):1666. doi: 10.3390/v15081666.
4
Advances in attractive therapeutic approach for macrophage activation syndrome in COVID-19.
Front Immunol. 2023 Jul 6;14:1200289. doi: 10.3389/fimmu.2023.1200289. eCollection 2023.
5
Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study.
Viruses. 2023 Mar 8;15(3):704. doi: 10.3390/v15030704.
6
The Benefits of Molnupiravir Treatment in Healthcare Facilities Patients with COVID-19.
Drug Des Devel Ther. 2023 Jan 19;17:87-92. doi: 10.2147/DDDT.S392708. eCollection 2023.
7
Current Treatments for COVID-19: Application of Supercritical Fluids in the Manufacturing of Oral and Pulmonary Formulations.
Pharmaceutics. 2022 Nov 4;14(11):2380. doi: 10.3390/pharmaceutics14112380.
8
Post-COVID Syndrome: The Research Progress in the Treatment of Pulmonary after COVID-19 Infection.
Pharmaceutics. 2022 May 26;14(6):1135. doi: 10.3390/pharmaceutics14061135.
9
Efficacy and safety of molnupiravir for COVID-19 patients.
Eur J Intern Med. 2022 Aug;102:118-121. doi: 10.1016/j.ejim.2022.05.024. Epub 2022 May 25.
10
Pregnancy and COVID-19, focus on vaccine and pharmacological treatment.
J Reprod Immunol. 2022 Jun;151:103630. doi: 10.1016/j.jri.2022.103630. Epub 2022 Apr 21.
Zotero 插件